Journavx (suzetrigine) / Vertex - LARVOL DELTA

Suzetrigine for the Treatment of Acute Pain: Comment. (PubMed, Anesthesiology) - No abstract available

Journal • Pain

Suzetrigine for the Treatment of Acute Pain: Comment. (PubMed, Anesthesiology) - No abstract available

Journal • Pain

Innovation Versus Consolidation: Critical Reflections on Suzetrigine and the Tramadol-Celecoxib Co-Crystal. (PubMed, J Pain Palliat Care Pharmacother) - No abstract available

Journal

Suzetrigine for the Treatment of Acute Pain: Comment. (PubMed, Anesthesiology) - No abstract available

Journal • Pain

Suzetrigine for the Treatment of Acute Pain: Reply. (PubMed, Anesthesiology) - No abstract available

Journal • Pain

A new era in pain management: suzetrigine's role in reducing opioid dependence. (PubMed, Ann Med Surg (Lond)) - No abstract available

Journal • Addiction (Opioid and Alcohol) • Pain

FDA approves Journavx (Suzetrigine) as the first non-opioid treatment for moderate to severe acute pain. (PubMed, Ann Med Surg (Lond)) - No abstract available

FDA event • Journal • Pain

Budget impact of suzetrigine for the treatment of moderate-to-severe acute pain in Medicaid-insured adults. (PubMed, J Med Econ) - "The addition of suzetrigine to formulary was estimated to result in a budget impact of -$2.8 M to -$8.3 M over two years, or -$0.11 to -$0.34 PMPM, translating to cost savings of $827 per patient treated with suzetrigine rather than an opioid over two years. While suzetrigine was estimated to increase drug costs, the associated avoidance of common opioid AEs and OUD/opioid abuse was estimated to result in cost savings for a state Medicaid plan in the first two years on formulary."

HEOR • Journal • Reimbursement • US reimbursement • Pain • Substance Abuse

Clinical Efficacy and Safety Profile of Suzetrigine: A Novel Non-opioid Analgesic Targeting NaV1.8 Sodium Channel. (PubMed, Cureus) - "Suzetrigine exhibits high selectivity for the NaV1.8 channel through a novel allosteric mechanism with significant pain relief compared to placebo and comparable efficacy to a standard hydrocodone/acetaminophen combination. Its recent approval by the U.S. Food and Drug Administration for moderate to severe acute pain underscores its potential as an effective non-opioid therapeutic. While its short-term efficacy and safety are well established, future research should focus on its long-term safety profile and its utility across a broader range of pain conditions."

Journal • Review • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry • NAV1

Use of Suzetrigine, a Selective Sodium Channel Blocker, in Postoperative Pain Management for an Adolescent Patient With Hereditary Neuropathy: A Case Report. (PubMed, A A Pract) - "His pain was well controlled with no side effects. Within 24 hours of stopping suzetrigine, the patient's pain rapidly intensified, suggesting suzetrigine's effectiveness in postoperative pain management in an adolescent patient with neuropathy."

Journal • Pain

A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Mayo Clinic

New P4 trial • Pain

Suzetrigine - A Novel FDA-Approved Analgesic - Opportunities, Challenges and Future Perspectives: A Perspective Review. (PubMed, Health Sci Rep) - "Moreover, this selectivity also constrains this medication to act on other receptors, thus possessing the least amount of adverse effects. Although Suzetrigine created many opportunities for research in the field of pain management, but also opened a door for many uncertainties that cannot be ignored."

FDA event • Journal • Addiction (Opioid and Alcohol) • Anesthesia • Pain • NAV1

Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures (clinicaltrials.gov) - P4 | N=80 | Enrolling by invitation | Sponsor: University of California, Irvine | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Musculoskeletal Diseases • Orthopedics • Pain

Suzetrigine, a Non-Opioid Small-Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science. (PubMed, Clin Transl Sci) - "It is the first non-opioid analgesic approved since celecoxib in 1998. Suzetrigine received approval for use in January 2025 in the United States only. Ongoing trials are exploring novel formulations, long-term safety, and integration into multimodal regimens for surgical and non-surgical pain."

Journal • Review • Addiction (Opioid and Alcohol) • Aesthetic Medicine • Anesthesia • CNS Disorders • Depression • Diabetic Neuropathy • Pain • Peripheral Neuropathic Pain • Psychiatry • NAV1

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy (clinicaltrials.gov) - P3 | N=734 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Incorporated

New P3 trial • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain

A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries (clinicaltrials.gov) - P4 | N=47 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting

Enrollment closed • Orthopedics • Pain

Suzetrigine for pain relief: Key considerations for nurses. (PubMed, Nursing) - "As suzetrigine becomes more widely available, health care professionals need to understand its benefits, risks, and proper use. This article provides an overview of its mechanism of action, adverse effects, dosing guidelines, cost considerations, and potential role in pain management."

Journal • Review • Pain • NAV1

Translational Human DRG Model Reveals Selective Efficacy of Nav1.8 Inhibitor Against Inflammatory Pain Responses (Neuroscience 2025) - "Using this method, we can show the efficacy of Nav 1.8 blockers like Suzetrigine and LTGO-33 in reducing an inflammation response. Contrarily, selective Nav 1.7 blockers like PF 05089771 do not show efficacy in reducing the inflammation response, but non-selective sodium channel blockers like TTX, Tetracaine or Lidocaine do. We believe that this platform can be used to screen sodium channel blocker efficacy against an inflammatory pain model as well as other ion channel modulators. Moreover, the use of primary human culture offers a large translational advantage over the traditional rodent models in achieving relevant insights into human biology."

Clinical • Late-breaking abstract • CNS Disorders • Pain • NAV1

Exploring Suzetrigine in the Preclinical Screening Platform for Pain (PSPP) Program (Neuroscience 2025) - "Additional recombinant targets have been evaluated for off-target activity, and PK experiments are in progress to determine exposure profiles. In summary, these new data will enable more extensive evaluation of the effects of Suzetrigine in vivo, within the PSPP program.The data generated in the program will be added to the public-facing PSPP database, which includes clinically used drugs and negative controls, with more data to be added as it is collected."

Late-breaking abstract • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Pain • Psychiatry • NAV1 • OPRM1

Molecular and Functional Characterization of hiPSC-Derived Dorsal Horn Neurons for Central Pain Target Discovery (Neuroscience 2025) - "While recent advances—such as the FDA approval of the NaV1.8 inhibitor Suzetrigine—have advanced analgesic discovery targeting peripheral nociceptors, therapeutic strategies addressing central mechanisms remain underexplored...All neurons displayed large voltage-gated sodium currents (~3,000 pA), and 81% exhibited miniature excitatory postsynaptic currents (mEPSCs), indicating synaptic activity and advanced maturation. Collectively, these results establish hiPSC-derived DHNs as a robust and scalable human platform for modeling central pain mechanisms, enabling high-content screening and therapeutic discovery for chronic pain conditions."

CNS Disorders • Pain • NAV1 • OPRM1 • PAX2

Biophysical characterization of the NaV1.9 Na+ channel in human sensory neurons (Neuroscience 2025) - "In human dorsal root ganglia (DRG), and trigeminal (TG) neurons, the tetrodotoxin (TTX)-sensitive NaV1.7, and TTX-resistant NaV1.8 play critical roles in the firing of action potentials, which drive electrical impulses to facilitate many downstream processes such as sensory perception, chronic itch, and pain. Here, we pharmacologically isolated and recorded the Nav1.9 currents, using both TTX and Suzetrigine (a potent, and selective NaV1.8 blocker), in human primary sensory neurons, and analyzed the biophysical properties of this channel. This information provides further insights into the Nav1.9 channel function which may aid future pharmacology and drug discovery efforts."

CNS Disorders • Musculoskeletal Pain • NAV1

Vx-548: a selective nav1.8 inhibitor with broad-spectrum efficacy against acute pain and neuropathic pain (Neuroscience 2025) - "In the postherpetic neuralgia model, VX-548 at a dose of 100 mg/kg was able to produce marked anti-allodynic responses. These results suggest that VX-548 produces robust, dose-dependent analgesic effects in diverse preclinical pain models, with particular efficacy in neuropathic settings."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Neuralgia • Pain • Psychiatry • NAV1

Pharmacological inhibition of NaV1.8 by suzetrigine reveals potent analgesic potential without tolerance development in mice. (PubMed, Mol Brain) - "Whole-cell recordings from dorsal root ganglion neurons revealed that suzetrigine inhibited tetrodotoxin (TTX)-resistant sodium currents in a concentration-dependent manner (IC50 = 0.35 ± 0.17 μM), consistent with high-affinity NaV1.8 inhibition. Importantly, repeated dosing did not produce tolerance in a chronic administration paradigm. Although suzetrigine showed limited efficacy in clinical trials for neuropathic pain, its robust analgesic effects in mouse models underscore the challenges of translating preclinical findings to human neuropathic pain, while still supporting the potential of NaV1.8-targeted therapies."

Journal • Preclinical • Immunology • Neuralgia • Pain • NAV1

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries (clinicaltrials.gov) - P4 | N=100 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting

Enrollment closed • Pain

Not Just Neurons: Pain Is Orchestrated in Partnership with Many Non-neuronal Cells. (PubMed, J Neurosci) - "Examples include monoclonal antibody and small molecule therapies disrupting calcitonin gene-related peptide signaling for treating migraine and, most recently, suzetrigine, a small molecular inhibitor of the voltage-gated sodium channel NaV1.8 subunit...One potential appeal of disrupting the activity of peripherally located non-neuronal cells is the likely bypassing of side effects associated with modulating a target receptor that is expressed by neurons within both the peripheral and central nervous systems, although targeting of peripheral, non-neuronal cells will not of course necessarily be side effect-free. Here, we examine the key roles of non-neuronal cells in orchestrating pain across a diverse set of conditions, from joint pain to bone pain, chemotherapy-induced neuropathic pain, Fabry disease, and chronic pain in general."

Journal • Licensing / partnership • CNS Disorders • Fabry Disease • Genetic Disorders • Migraine • Musculoskeletal Diseases • Musculoskeletal Pain • Neuralgia • Orthopedics • Pain • NAV1